- This event has passed.
CART Cell Therapy for Acute Lymphoblastic Leukemia | Rawan Faramand, MD
Rawan Faramand, MD
Assistant Member
H. Lee Moffitt Cancer Center
Dr. Faramand is an assistant member in the Department of Blood and Marrow Transplant and Cellular Immunotherapy (BMT-CI). She earned her medical degree from Virginia Commonwealth University and completed her internal medicine residency at the University of Maryland where she served as chief resident. She went on to complete her Hematology/Oncology followship at University of South Florida/Moffitt Cancer Center serving as chief fellow.
She is actively engaged in clinical care and research. Her clinical interest focuses on allogeneic stem cell transplantation and cellular immunotherapy for patients with hematologic malignancies, particularly acute lymphoblastic leukemia. Her research focuses on identifying predictive markers of toxicity for patients treated with cellular immunotherapy. She is the principal investigator of multiple investigational trials in addition to several observational studies.
Dr. Faramand’s Objectives
At the conclusion of this activity, participants will be able to
-
- Analyze treatment landscape of relapsed/refractory B-ALL
- Illustrate CAR T cell therapy for adolescents and young adults (AYA) with R/R B-ALL
- Explain novel cell therapies for R/R ALL
Faculty Disclosure
Dr. Faramand has indicated the following relevant financial relationships with commercial interests
Commercial Interest/Organization Financial Relationship
- Autolus & Sanofi Advisor
- Kite/Gilead Consultant
Planning Committee Disclosure
Dr. Lekakis has indicated that he has no relevant financial relationships with commercial interests.
Target Audience
Faculty, Primary Care Physicians, APRNs, PharmD
Accreditation
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.